CA Patent

CA2921160C — Combination formulation of two antiviral compounds

Assigned to Gilead Sciences Inc · Expires 2021-04-13 · 5y expired

What this patent protects

Disclosed are pharmaceutical compositions comprising Compound I, having the formula (I): and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.

USPTO Abstract

Disclosed are pharmaceutical compositions comprising Compound I, having the formula (I): and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.

Drugs covered by this patent

Patent Metadata

Patent number: CA2921160C
Jurisdiction: CA
Classification: —
Expires: 2021-04-13
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.